Psychiatry and Neurology, Neurology · Cullman, AL
NPI
1811931546
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1809 Kress Street
Cullman, AL, 35058
Phone (256) 739-1210
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.6M
217,756 services
Medicare patients, 2024
554
Average age 63
Drug cost, 2024
$20.4M
44,438 prescriptions
Company payments, 2025
$106K
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher C Laganke was code J2323 (injection, natalizumab, 1 mg), 108,900 times for 45 patients. In total Christopher C Laganke billed 217,756 services in 52 codes, and Medicare paid $5.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2323 Injection, natalizumab, 1 mg | Office | 108,900 | 45 | $18.48 | $2.0M |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 27,700 | 45 | $4.28 | $118K |
| J2350 Injection, ocrelizumab, 1 mg | Office | 27,000 | 29 | $42.12 | $1.1M |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 16,200 | 20 | $36.68 | $594K |
| J0586 Injection, abobotulinumtoxina, 5 units | Office | 7,840 | 13 | $6.84 | $54K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 6,572 | 46 | $0.21 | $1,411 |
| 96365 Intravenous Infusion, Hydration | Office | 744 | 81 | $41.88 | $31K |
| 99214 Office E&M - Established | Office | 676 | 433 | $71.91 | $49K |
| 96366 Intravenous Infusion, Hydration | Office | 575 | 29 | $13.99 | $8,045 |
| 96375 Injection Administration | Office | 157 | 51 | $10.52 | $1,651 |
| 96415 Chemotherapy Administration | Office | 151 | 40 | $18.99 | $2,867 |
| 96413 Chemotherapy Administration | Office | 148 | 59 | $76.16 | $11K |
| 64615 Musculoskeletal | Office | 93 | 32 | $87.20 | $8,109 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 58 | 17 | $0.40 | $23.22 |
| 64616 Musculoskeletal | Office | 45 | 21 | $114.82 | $5,167 |
By year: 2022 $6.9M for 252,786 services; 2023 $6.4M for 234,828 services; 2024 $5.6M for 217,756 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 14 | 14 | $2.92 | $40.92 |
Medicare prescription drug claims, 2024
In 2024, the drug Christopher C Laganke prescribed most often to Medicare patients was Dextroamphetamine-Amphetamine (Dextroamphetamine/Amphetamine), with 3,056 prescriptions and refills. In total Christopher C Laganke wrote 44,438 Medicare prescriptions that cost $20.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 3,056 | 3,071 | 397 | $113K |
| Baclofen Generic | 2,189 | 3,075 | 425 | $45K |
| Lacosamide Generic | 2,050 | 2,161 | 361 | $248K |
| Alprazolam Generic | 1,565 | 1,570 | 207 | $8,953 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,482 | 1,482 | 160 | $36K |
| Clonazepam Generic | 1,433 | 1,439 | 203 | $10K |
| Gabapentin Generic | 1,277 | 1,412 | 206 | $17K |
| Dalfampridine Er Dalfampridine | 965 | 1,216 | 159 | $387K |
| Tizanidine Hcl Generic | 886 | 1,209 | 141 | $18K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 815 | 817 | 93 | $67K |
| Armodafinil Generic | 752 | 772 | 167 | $46K |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | 666 | 668 | 102 | $30K |
| Primidone Generic | 573 | 844 | 110 | $14K |
| Pregabalin Generic | 570 | 617 | 90 | $11K |
| Oxcarbazepine Generic | 556 | 717 | 98 | $26K |
Brand drugs: 6,792 claims; generic drugs: 37,610 claims; opioid claims: 3,408.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher C Laganke $106K ($106K in general payments such as food, travel and fees) from 37 companies. The largest payer was EMD Serono, Inc. with $70K.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 41 | $70K |
| Biogen, Inc. BIIB | 30 | $20K |
| TG Therapeutics, Inc. TGTX | 22 | $12K |
| UCB, Inc. UCB.BR | 73 | $685 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $301 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $290 |
| Genzyme Corporation SNY | 11 | $265 |
| Mallinckrodt Hospital Products Inc. | 10 | $237 |
| Neurelis, Inc. | 9 | $205 |
| Argenx US, Inc. ARGX | 12 | $204 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.